BioCentury’s roundup of translational innovations

Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space

Plus new indications recommended for Bimzelx and Cosentyx, and younger populations recommended for seven medicines

Along with its successor to blockbuster Trikafta in CF, the biotech is advancing a diversified pipeline encompassing pain, hematology and kidney disease

Three submissions are under FDA priority review

a16z, Deerfield co-lead $65M series A for UC Berkeley spinout’s small molecule deubiquitination platform

Pharmaceutical companies balancing calls to disengage vs. duties to patients

How Sanofi spinout will deploy $150M to advance CFTR stabilizers to treat cystic fibrosis

Montreal-based newco is cataloging properties of misfolded proteins and building a virtual chemical library to screen for stabilizers

Vertex alum Beth Hoffman’s newco designing protein degraders and correctors for neuroscience indications